Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome

A Concise Review

William T. Johnson; Reetu Mukherji; Saritha Kartan; Neda Nikbakht; Pierluigi Porcu; Onder Alpdogan


Chin Clin Oncol. 2019;8(1) 

In This Article


HSCT for advanced CTCL has made significant strides over the past 30 years, and it remains the only curative approach. Unfortunately, our data and experience are limited to small scale retrospective analyses, case reports and meta-analyses all of which have different conditioning regimens, GVHD prophylaxis, response criteria and types of donors. Clinical trials addressing the optimal timing of HSCT prior to or vs. front-line systemic therapies as well as post-transplant maintenance studies are clearly needed. Additionally, dedicated prospective prognostication studies such as the ongoing PROCLIPI study hope to identify the subsets of patients who will have more aggressive clinical courses,[7,56] some of whom may ultimately be appropriate for earlier HSCT strategies even without advanced stage disease at diagnosis.